Pa­tient death spurs tri­al halt for Ma­gen­ta Ther­a­peu­tics

Ma­gen­ta Ther­a­peu­tics is paus­ing an ear­ly-stage clin­i­cal tri­al af­ter a pa­tient died. The death was deemed to be pos­si­bly re­lat­ed to its drug, MG­TA-117.

The biotech said the pause of the Phase I/II tri­al is vol­un­tary and gives it time to re­view all avail­able da­ta be­fore de­cid­ing what to do next. It’s al­so re­port­ed the known in­for­ma­tion to the FDA.

The dose-es­ca­la­tion tri­al was de­signed to test whether MG­TA-117, an an­ti­body-drug con­ju­gate, could serve as a more tar­get­ed al­ter­na­tive to high-in­ten­si­ty chemother­a­py as a con­di­tion­ing agent for can­cer pa­tients who are set to re­ceive a stem cell trans­plant. It re­cruit­ed pa­tients with re­lapsed/re­frac­to­ry acute myeloid leukemia and myelodys­plas­tic syn­drome.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.